An FDA advisory committee voted to add six of seven reviewed peptides to the agency's bulk-drug-substance list [1].

This move could shift thousands of wellness products from the unregulated gray market into legal, specialized pharmacy channels. By easing compounding restrictions, the U.S. government aims to provide safer, monitored access to substances that are already widely used despite lacking formal approval.

The Pharmacy Compounding Advisory Committee reached the decision during a two-day meeting that concluded on Friday afternoon [2, 5]. The panel's recommendation specifically includes BPC-157, a peptide often sought for its purported healing properties [6].

While the committee supported most of the substances under review, the vote to ease these restrictions was described as narrowly in favor [2]. One of the seven peptides was rejected for addition to the list [1].

Under current regulations, adding a substance to the 503A bulk-drug-substance list allows pharmacists to compound the drug for individual patients more easily. This process reduces the regulatory hurdles that currently drive consumers toward unverified online sellers.

Despite the committee's recommendation, the decision is not yet final. The vote is non-binding and still requires official sign-off from the FDA [3]. The agency will now review the committee's findings before determining whether to update the compounding list.

“Six of seven reviewed peptides were recommended for addition to the bulk-drug-substance list”

This recommendation represents a pragmatic shift in regulatory strategy. By moving popular peptides from the gray market into the regulated compounding pharmacy system, the FDA can improve oversight of purity and dosage without requiring the full, multi-year clinical trial process of a new drug application. If the FDA accepts the non-binding vote, it will likely increase the availability of these substances through legal prescriptions while decreasing the reliance on unregulated third-party vendors.